<DOC>
	<DOCNO>NCT02468492</DOCNO>
	<brief_summary>The purpose study evaluate affect platelet rich plasma molecular cellular function knee joint .</brief_summary>
	<brief_title>Pilot Synovial Fluid Molecular/Stem Cell Response PRP Knee Osteoarthritis : Clinical &amp; Imaging Outcome Correlation</brief_title>
	<detailed_description>In study 18 subject mild moderate symptomatic knee osteoarthritis recruit per IRB approve protocol explicit inclusion exclusion criterion . Subjects enrol meet criterion blind randomize ( 2:1 ) receive Platelet Rich Plasma normal saline `` control '' . Prior intervention , synovial fluid aspiration occur . At follow number one ( approximately 10 day baseline ) repeat aspiration occur differential analysis molecular biochemical effect undertake ; data serve primary outcome measure . This data correlate clinical imaging outcome measure secondary outcome measure complete baseline intermittently throughout study . The duration study one year .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>1 . Early/Mild Moderate Stage knee osteoarthritis ( KOA ) , determine KellgrenLawrence Grade 2 3 PA stand radiograph within past three month ; A prospective subject diagnosis nonend stage KOA ( i.e. , potential study candidate ) express interest participate XRAY within specify timeperiod sent fresh XRAY . This XRAY read radiologist &amp; pay study . 2 . &gt; =40 year age ; 3 . Average 100point VAS score &gt; 50 , average , within past 3 months* , KOA felt primary contributor pain . Alternate 10point scale pain score average &gt; 5 may consider prospective subject also complete VAS score &gt; 50 screening . 4 . Exam consistent KOA primary etiology pain ; 5 . No sign inflammatory arthropathy medical record , history physical examination ; 6 . A &gt; 3 millimeter intraarticular ( IA ) effusion present ultrasound evaluation . 7 . [ If chronic liver renal disease patient , evidence stable disease over/within past six month , else exclusion . ] 8 . Veteran receive care McGuire VAMC . 1 . Morbid obesity ( BMI &gt; 40 ) ; 2 . Poorly control diabetes ( hemoglobin A1C &gt; 7.5 fast blood glucose &gt; 200 ) last 6 month ; 3 . Ipsilateral knee surgery , trauma within last 6 month , corticosteroid injection within 3 month . 4 . 4 . History inflammatory arthropathy ( RA , SLE crystalline arthritis knee ) ** ; 5 . Any rheumatoid arthritis gout diagnosis exclusionary . 6 . Current infection affect joint uncontrolled untreated active infection . 7 . Moderate severe anemia ( hemoglobin &lt; 11 g/dl ) thrombocytopenia ( platelet count &lt; 100,000 ) ; Hemoglobin &gt; 17 g/dl &lt; 11 g/dl and/or platelet count &gt; 500,000 &lt; 100,000 platelets/Î¼l . [ CBC obtain within 6 month require , even obtain initial screening visit . ] 8 . Individuals dialysis , liver failure , uncontrolled renal liver disease exclude . In chronic renal liver disease , documentation stable disease within recent 6 month require . 9 . Individuals therapeutic anticoagulant ( e.g. , Warfarin , Dabigatran , Enoxaparin ) history coagulopathy exclude . Per standard clinical practice , subject antiplatelet therapy exclude . 10 . Pregnancy breastfeeding ; Female subject childbearing potential must negative pregnancy screen prior enrollment . Female subject childbearing potential must confirm actively breastfeed prior enrollment . 11 . Current illicit drug abuse / active alcohol abuse ( i.e , Current substance abuse ) ; 12 . Uncontrolled psychiatric disorder ; 13 . Lack transportation ( i.e. , get to/from appointment VAMC ) and/or willingness attend study appointment ( screening/consent , Intervention , Day10followup , Month6 followup , visit overthephone / inperson / via Telehealth Month3 Month12 ; 14 . Advanced currently active cancer . 15 . Blood disorder ( Sickle Cell Anemia , TTP , others ) 16 . Vulnerable population : Individuals incapable make informed decision enrol , form incarceration .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Knee Osteoarthritis</keyword>
	<keyword>Platelet Rich Plasma</keyword>
	<keyword>Mechanism Action</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Synovial Fluid</keyword>
</DOC>